Pharma

Abpro Collaborated with Celltrion to Develop and Commercialize ABP 102 for the Treatment of HER2+ Cancer

Abpro Collaborated with Celltrion to Develop and Commercialize ABP 102 for the Treatment of HER2+ Cancer

Shots: Abpro to receive ~$1.75B incl. an equity investment, development, and comme...

Merck KGaA Entered into Option to License Agreement with Nerviano Medical Sciences to Develop NMS-293

Merck KGaA Entered into Option to License Agreement with Nerviano Medical Sciences to Develop NMS-293

Shots: NMS to receive ~$65M up front and option exercise fees & is also eligib...

CytoReason Expands its 2019 Collaboration with Pfizer for AI Drug Development

CytoReason Expands its 2019 Collaboration with Pfizer for AI Drug Development

Shots: CytoReason to receive a $20M equity investment while Pfizer gets the right...

Image